Pharmacokinetics of Efavirenz 600mg in Combination with Rifampicin in Chinese HIV/TB Co-Infection Patients

References

• World Health Organization. Global Tuberculosis Reports 2021. Geneva, Switzerland: World Health Organization; 2021. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021. Accessed July 6, 2021.
   Google Scholar
• World Health Organization. Tuberculosis. Geneva, Switzerland: World Health Organization; 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/tuberculosis. Accessed December 1, 2021.
   Google Scholar
• Coelho L, Cardoso SW, Amancio RT, et al. Trends in AIDS-defining opportunistic illnesses incidence over 25 years in Rio de Janeiro, Brazil. PLoS One. 2014;9:e98666. doi:10.1371/journal.pone.0098666
   PubMed Web of Science ®Google Scholar
• Borand L, Madec Y, Laureillard D, et al. Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial). PLoS One. 2014;9:e90350. doi:10.1371/journal.pone.0090350
   PubMed Web of Science ®Google Scholar
• Habtewold A, Makonnen E, Amogne W, et al. Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study. Pharmacogenomics. 2015;16:1047–1064. doi:10.2217/pgs.15.35
   PubMed Web of Science ®Google Scholar
• López-Cortés LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002;41:681–690. doi:10.2165/00003088-200241090-00004
   PubMed Web of Science ®Google Scholar
• Lee KY, Lin SW, Sun HY, et al. Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy. PLoS One.2014;9(2):e88497 doi:10.1371/journal.pone.0088497.
   PubMed Web of Science ®Google Scholar
• Acquired Immunodeficiency Syndrome and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association, Chinese Center for Disease Control and Prevention. Chinese Guidelines for Diagnosis and Treatment of Human Immunodeficiency Virus Infection/Acquired Immunodeficiency Syndrome(2021 edition). Medical Journal of Peking Union Medical College Hospital. 2022;13(2):203–226. doi:10.12290/xhyxzz.2022-0097
   Google Scholar
• Keizer RJ, Zandvliet AS, Beijnen JH, Schellens JH, Huitema AD. Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses. AAPS J. 2012;14:601–611. doi:10.1208/s12248-012-9373-2
   PubMed Web of Science ®Google Scholar
• Zhang J, Hayes S, Sadler BM, et al. Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. Br J Clin Pharmacol. 2015;80:502–514. doi:10.1111/bcp.12639
   PubMed Web of Science ®Google Scholar
• Dooley KE, Denti P, Martinson N, et al. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. J Infect Dis. 2015;211:197–205. doi:10.1093/infdis/jiu429
   PubMed Web of Science ®Google Scholar
• Dooley KE, Flexner C, Andrade AS. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. J Infect Dis. 2008;198:948–961. doi:10.1086/591459
   PubMed Web of Science ®Google Scholar
• Luetkemeyer AF, Rosenkranz SL, Lu D, et al. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013;57:586–593. doi:10.1093/cid/cit246
   PubMed Web of Science ®Google Scholar
• Gengiah TN, Holford NH, Botha JH, Gray AL, Naidoo K, Abdool Karim SS. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. Eur J Clin Pharmacol. 2012;68:689–695. doi:10.1007/s00228-011-1166-5
   PubMed Web of Science ®Google Scholar
• Orrell C, Cohen K, Conradie F, et al. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy. Antivir Ther. 2011;16:527–534. doi:10.3851/IMP1780
   PubMed Web of Science ®Google Scholar
• Liu J, Chan-Tack K, Jadhav P, et al. Why did the FDA approve efavirenz 800 mg when co-administered with rifampin? Int J Clin Pharmacol Ther. 2014;52:446–453. doi:10.5414/CP202079
   PubMed Web of Science ®Google Scholar
• Brennan-Benson P, Lyus R, Harrison T, Pakianathan M, Macallan D. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. AIDS. 2005;19:1541–1543. doi:10.1097/01.aids.0000183519.45137.a6
   PubMed Web of Science ®Google Scholar
• McIlleron HM, Schomaker M, Ren Y, et al. Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype. AIDS. 2013;27:1933–1940. doi:10.1097/QAD.0b013e328360dbb4
   PubMed Web of Science ®Google Scholar
• Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS. 2005;19:1481–1486. doi:10.1097/01.aids.0000183630.27665.30
   PubMed Web of Science ®Google Scholar
• Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph S. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. HIV Med. 2008;9:294–299. doi:10.1111/j.1468-1293.2008.00563.x
   PubMed Web of Science ®Google Scholar
• Stott KE, Pertinez H, Sturkenboom M, et al. Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. J Antimicrob Chemother. 2018;73:2305–2313. doi:10.1093/jac/dky152
   PubMed Web of Science ®Google Scholar
• Svensson EM, Svensson RJ, Te Brake L, et al. The Potential for Treatment Shortening With Higher Rifampicin Doses: relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. Clin Infect Dis. 2018;67:34–41. doi:10.1093/cid/ciy026
   PubMed Web of Science ®Google Scholar
• Bertrand J, Verstuyft C, Chou M, et al. Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia. J Infect Dis. 2014;209:399–408. doi:10.1093/infdis/jit466
   PubMed Web of Science ®Google Scholar
• Berhan A, Berhan Y, Yizengaw D. A meta-analysis of drug resistant tuberculosis in Sub-Saharan Africa: how strongly associated with previous treatment and HIV co-infection. Ethiop J Health Sci. 2013;23:271–282. doi:10.4314/ejhs.v23i3.10
   PubMedGoogle Scholar